WASHINGTON DC—Patients with metastatic breast cancer who are HER-2 positive could potentially be treated with the anti-HER-2 conjugated drug, trastuzumab-emtansine (T-DM1), alone — without needing to add chemotherapy. This prediction was made at the American Association for Cancer Research annual conference by Dr Jose Baselga Physician in Chief at New York’s Memorial Sloan-Kettering Cancer Center on the basis of data the EMILIA study (which led to the approval of this agent in the USA in 2013). He gave Peter Goodwin details about the effectiveness of this new agent in the presence of PI-3 kinase mutations.
You may also like...
Stage I to III breast cancer: radiation therapy to chest lymph nodes extends life 26 Oct, 2013 Superior Survival in Conservatively Treated Male Breast Cancer 13 Jul, 2018 ASCO Audio Journal of Oncology – June 4th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6; in the company of Julie Gralow 3 Jun, 2006 Low risk prostate cancer: less treatment means lower cost, and better patient outcomes 16 Mar, 2013
- Previous story Two-step immunotherapy brings promise in advanced ovarian cancer
- Next story Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014